Printer Friendly

Beckman Coulter Announces Test to Help Assess Cardiac Risk and Other Diseases.

Business Editors and Health/Medical Writers

FULLERTON, Calif.--(BW HealthWire)--March 6, 2002

Beckman Coulter, Inc. (NYSE:BEC) announced today it has released a new high-sensitivity laboratory test to help physicians determine a patient's risk of coronary artery disease.

The test -- called CRPH -- accurately measures levels of C-reactive protein (CRP), a protein produced in the liver and released into the bloodstream as a result of infection or injury, such as tissue damage or inflammation caused by coronary artery disease.

"CRPH can be performed as part of a routine, physical exam to help physicians identify individuals at increased risk of coronary artery disease," said Wing Pang, vice president-director of Beckman Coulter's clinical chemistry development center. "Studies show that more traditional cardiac screening methods identify only 50 percent of individuals with a predisposition to future coronary events. But performing high-sensitivity CRP testing in conjunction with these other screening methods -- such as tests that measure cholesterol, body weight and blood pressure -- can dramatically improve a physician's ability to assess risk of cardiovascular disease."

The new test also can aid physicians in the evaluation of stress, trauma, infection, inflammation, surgery and associated diseases.

The CRPH test is available on the company's IMMAGE(R) immunochemistry system and SYNCHRON LX(R)20 PRO chemistry analyzer.

CRPH is Beckman Coulter's second test for cardiac evaluation released in the last 12 months. In June 2001, the company launched Access(R) AccuTnI(TM), a troponin I test that aids in the diagnosis and treatment of heart attacks and cardiac muscle damage. The 12-minute test, which is one of the fastest available, is used by hospitals in routine and emergency situations. Access AccuTnI is available on Beckman Coulter's Access immunoassay systems.

Beckman Coulter, Inc. is a global biomedical company headquartered in Fullerton, Calif. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62 percent of this amount generated by recurring revenue from supplies, chemistry kits and services. For more information, visit
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 6, 2002
Previous Article:Penn National Gaming to Participate in Lehman Brothers 2002 High Yield Conference.
Next Article:Small Town Radio/Worldwide PetroMoly Debuts New Radio Network.

Related Articles
Beckman Coulter and Bio-Rad Agree to New Access Immunoassay System Distribution Arrangement.
XTRANA and Beckman Coulter Enter Agreement to Offer Novel Automated Nucleic Acid Extraction System.
Beckman Coulter Receives FDA Clearance to Market New Cardiac Test; 12-Minute Test One of the Fastest Available.
Beckman Coulter Launches Immunoassay System with Networking Technology and Extensive Menu of Diagnostic Tests.
Beckman Coulter and EpiVax Form Strategic Alliance.
Beckman Coulter Combines Chemistry and Immunoassay Testing On Single Platform; New SYNCHRON LXi 725 System Paves Way for Safer, More Efficient...
Beckman Coulter Receives FDA Clearance to Expand Use of Cardiac Test; Highly Sensitive Troponin I Test Can Now Help Physicians Determine Patient Risk...
Beckman Coulter Launches Ovarian Cancer Test, Expands Tumor Marker Menu on Immunoassay Systems.
Beckman Coulter Enters High-Volume Immunoassay Market with New, Random-Access System for Diagnostic Labs.
Beckman Coulter and AmeriNet Renew $60 Million Immunoassay Agreement.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters